ArticleOncoimmunology2013
Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.Signal transduction and targeted therapy · 2026Review
- Tumor microenvironment antigens.Seminars in immunopathology · 2023Review
- Review
- Re-defining T-Cell Exhaustion: Subset, Function, and Regulation.Immune network · 2020Review
- Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?Cell medicine · 2019Review
- Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Current hematologic malignancy reports · 2016Review
- The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.Oncotarget · 2016Article
- PD-L1-specific T cells.Cancer immunology, immunotherapy : CII · 2016Review
- Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.Oncoimmunology · 2016Review
- Trial Watch: Adoptive cell transfer for oncological indications.Oncoimmunology · 2015Review
- Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State.Vaccines · 2015Review
- Trial Watch: Peptide-based anticancer vaccines.Oncoimmunology · 2015Review
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.Oncoimmunology · 2015Review
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Novel immune checkpoint blocker approved for the treatment of advanced melanoma.Oncoimmunology · 2014Article
- Trial Watch: Lenalidomide-based immunochemotherapy.Oncoimmunology · 2013Review
- The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.Journal of hematology & oncology · 2013Review
- Trial Watch: Immunostimulatory cytokines.Oncoimmunology · 2013Review
- Trial watch: Oncolytic viruses for cancer therapy.Oncoimmunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The blockade of the PD-1 pathway can increase the production of interferon γ by tumor-specific T cells located within or in the proximity of the malignant lesion, thereby increasing the chemokine-dependent trafficking of immune effector cells. This can boost the efficacy of adoptive T-cell therapy to achieve superior antitumor responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.